Antisense Apolipoprotein B-100 As Novel Treatment For Hypercholesterolemia: Focus On Isis 301012

Bibliography

• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97, 1440–1445 (1998).
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
   Google Scholar
• Grodos D, Tonglet R: Scandinavian simvastatin study (4S). Lancet 344(8939–8940), 1768 (1994).
   Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009 (1996).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267–1278 (2005).
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
   Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294, 2437–2445 (2005).
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (LTAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459–467 (2000).
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al.: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107, 2409–2415 (2003).
   Google Scholar
• Davidson MH, McGarry T, Bettis R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2125–2134 (2002).
   Google Scholar
• Elovson J, Chatterton JE, Bell GT et al.: Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J. Lipid Res. 29, 1461–1473 (1988).
   Google Scholar
• Crooke ST: Antisense drug technology. In: Principles, Strategies, and Applications. Crooke ST (Eds.) Marcel Dekker, Inc. NY, USA (2001).
   Google Scholar
• Crooke ST: Progress in antisense technology. Annu. Rev. Med. 55, 61–95 (2004).
   Google Scholar
• Bennett CF, Cowsert LM: Antisense oligonucleotides as a tool for gene functionalization and target validation. Biochim. Biophys. Acta 1489, 19–30 (1999).
   Google Scholar
• Dashti N, Gandhi M, Liu X, Lin X, Segrest JP: The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry 41, 6978–6987 (2002).
   Google Scholar
• Young SG: Recent progress in understanding apolipoprotein B. Circulation 82, 1574–1594 (1990).
   Google Scholar
• Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG: Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N. Engl. J. Med. 338, 1577–1584 (1998).
   Google Scholar
• Veerkamp MJ, de GJ, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF: Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler. Thromb. Vasc. Biol. 22, 274–282 (2002).
   Google Scholar
• Schonfeld G, Lin X, Yue P: Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol. Life Sci. 62, 1372–1378 (2005).
   Google Scholar
• Di LE, Magnolo L, Lancellotti S et al.: Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia. J. Med. Genet. 44, 219–224 (2007).
   Google Scholar
• Farese RV, Jr, Linton MF, Young SG: Apolipoprotein B gene mutations affecting cholesterol levels. J. Intern. Med. 231, 643–652 (1992).
   Google Scholar
• Schonfeld G: The hypobetalipoproteinemias. Annu. Rev. Nutr. 15, 23–34 (1995).
   Google Scholar
• Geary RS, Watanabe TA, Truong L et al.: Pharmacokinetic properties of 2'-O-(2- methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890–897 (2001).
   Google Scholar
• Graham MJ, Crooke ST, Monteith DK et al.: In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther. 286, 447–458 (1998).
   Google Scholar
• Yu RZ, Zhang H, Geary RS et al.: Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J. Pharmacol. Exp. Ther. 296, 388–395 (2001).
   Google Scholar
• Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ: An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872–884 (2005).
   Google Scholar
• Suppression of apolipoprotein (Apo)B-100 mRNA by an antisense oligonucleotide reduces total cholesterol and LDL cholesterol LDL-C without causing hepatic steatosis in mice.
   Google Scholar
• Kastelein JJ, Wedel MK, Baker BF et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729–1735 (2006).
   Google Scholar
• First to describe the efficacy and safety of short-term administration of an antisense oligonucleotide to human ApoB in healthy volunteers.
   Google Scholar
• Chuang E, Lemonidas K, Whipple CP et al.: A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing human apoB-100 transgene. Atheroscler. Suppl. (2007) (Abstract).
   Google Scholar
• Graham M, Tae-won K, Lemonidas K, Subramaniam A, Crooke R: Suppression of apoB by antisense oligonucleotides produces concomitant downstream reductions in lipogenic genes in mice and nonhuman primates. Circ. Res. 97(11) (2005) (Abstract 5010).
   Google Scholar
• Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114 (2006).
   Google Scholar
• Bradley J, Crooke R, Graham M, Wedel M: Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of ApoB in healthy volunteers. Circulation 112 (2005) (Abstract 727).
   Google Scholar
• Geary R, Yu R, Bradley J, Chuang E, Wedel M, Vanvliet A: Lack of pharmacokinetic interactions of an antisense oligonucleotide targeting human apoB, when coadmistered with simvastatin and ezetemibe, in man. Atheroscler. Suppl. (2006) (Abstract).
   Google Scholar
• Cuchel M, Bloedon LT, Szapary PO et al.: Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148–156 (2007).
   Google Scholar
• Describes the effect of microsomal tranfer protein inhibition in patients with homozygous familial hypercholesterolemia. Significant reduction in LDL-C and ApoB were observed. These reductions were accompanied by accumulation of hepatic fat.
   Google Scholar
• Yue P, Tanoli T, Wilhelm O, Patterson B, Yablonskiy D, Schonfeld G: Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21. Metabolism 54, 682–688 (2005).
   Google Scholar
• Crooke RM: Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin. Biol. Ther. 5, 907–917 (2005).
   Google Scholar